Overview
Exposure to fine particulate matter (PM2.5) air pollution is an established risk factor for cardiovascular (CV) morbidity.
Description
This is a randomized double-blind placebo-controlled (sham filtration) crossover trial comparing the effectiveness bedroom-only portable indoor air filtration units [AFUs] to reduce personal PM2.5 exposures and improve cardiometabolic health. The health benefits (primary outcome: resting BP) will be evaluated over acute (4-day) and long-term (4-week) periods in 50 nonsmoking elderly adults living in a senior facility impacted by near-roadway pollutants.
Eligibility
Inclusion Criteria:
- Nonsmoker
- ≥60 years old
- residing in Carpenter Place Apartments
Exclusion Criteria:
- Active cigarette smoker
- daily secondhand smoke exposure (self-report)
- any CV event (myocardial infarction, stroke, heart failure, revascularization) in the past 3 months
- unstable CV condition or risk factor (uncontrolled diabetes, class 3-4 angina or heart failure) or any medical condition that would place the participant at risk from participation or jeopardize study integrity (per investigators)
- expected overnight travel outside their apartment during the 14-week study period
- unable to provide informed consent
- lung disease requiring oxygen
- renal dialysis
- cancer receiving active treatment or chemotherapy
- severe uncontrolled high BP ≥160/100 mm Hg or SBP<115 mm Hg.
- CV medication change in the prior month. If participants are on medications for high BP, diabetes, or a CV condition, they will need to have stable therapy during the prior month with no planned changes during the study period.